Scholarlink

<p>Tertiary lymphoid structures (TLSs) facilitate tumor microenvironment immune interactions. While TLSs and their associated gene signatures correlate with better response to immune checkpoint inhibitors (ICIs), the complex transcriptomic interplay/co-regulation among these factors remains under investigation. We analyzed correlations between survival and transcriptome expression (35 immunoregulatory factors associated with B/T cells and TLSs) in 217 patients with ICI-treated solid tumors. Denser correlations among B/T cell markers, immune checkpoints, and TLS-related molecules was associated with longer survival. High CXCL13 (B-lymphocyte chemoattractant) expression correlated with longer overall survival (hazard ratio [HR] 0.46 [95% CI: 0.27–0.81], <i>p</i> = 0.006) in 217 ICI-treated patients but not in 272 ICI-naïve patients (HR 0.85 [0.52–1.40], <i>p</i> = 0.519), suggesting its potential predictive/ICI-related, rather than prognostic, value. Overall, patients with highly coordinated T- and B-cell activity, checkpoints, and TLS-related molecules, and higher CXCL13 expression demonstrated prolonged survival after ICIs. Comprehensive multiomics and tumor immunomic profiling may better predict outcome after immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Orchestration of B and T cells predicts prolonged survival after cancer immune checkpoint inhibitor therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月28日

查看全文
  • Yu Fujiwara,
  • Shumei Kato,
  • Daisuke Nishizaki,
  • Hirotaka Miyashita,
  • Suzanna Lee,
  • Taylor J. Jensen,
  • Paul DePietro,
  • RJ Seager,
  • Sadakatsu Ikeda,
  • Razelle Kurzrock

摘要

Tertiary lymphoid structures (TLSs) facilitate tumor microenvironment immune interactions. While TLSs and their associated gene signatures correlate with better response to immune checkpoint inhibitors (ICIs), the complex transcriptomic interplay/co-regulation among these factors remains under investigation. We analyzed correlations between survival and transcriptome expression (35 immunoregulatory factors associated with B/T cells and TLSs) in 217 patients with ICI-treated solid tumors. Denser correlations among B/T cell markers, immune checkpoints, and TLS-related molecules was associated with longer survival. High CXCL13 (B-lymphocyte chemoattractant) expression correlated with longer overall survival (hazard ratio [HR] 0.46 [95% CI: 0.27–0.81], p = 0.006) in 217 ICI-treated patients but not in 272 ICI-naïve patients (HR 0.85 [0.52–1.40], p = 0.519), suggesting its potential predictive/ICI-related, rather than prognostic, value. Overall, patients with highly coordinated T- and B-cell activity, checkpoints, and TLS-related molecules, and higher CXCL13 expression demonstrated prolonged survival after ICIs. Comprehensive multiomics and tumor immunomic profiling may better predict outcome after immunotherapy.